AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Bullfrog AI Holdings, Inc. Common Stock

$0.47 -$0.41 (-46.47%)
NASDAQ · 14 Sep 2026 20:00 UTC
Previous Close
$0.48
Day Range
$0.47$0.49
Year Range
$0.42$2.04
Market Cap
8.74M
AVG Volume
237.15K
Trailing/Forward PE
-1/-
PEG ratio
0.02
Dividend Yield
-
Next Earnings Date
2026-11-13
Primary Exchange
NASDAQUS
Revenue (USD) · TTM
0100K200K300K24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
BFRG Revenue (USD) · TTM by quarter
PeriodRevenue (USD) · TTM
26 Q2298.8K
26 Q1116.67K
25 Q4116.67K
25 Q3116.67K
25 Q233.26K
25 Q10
24 Q40
24 Q30
24 Q265K
24 Q165K
Net Income (USD) · TTM
-8M-6M-4M-2M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
BFRG Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
26 Q2-6M
26 Q1-6.07M
25 Q4-6.5M
25 Q3-6.73M
25 Q2-6.94M
25 Q1-7.11M
24 Q4-6.99M
24 Q3-6.58M
24 Q2-6.07M
24 Q1-5.93M
Operating Income (USD) · TTM
-8M-6M-4M-2M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
BFRG Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
26 Q2-6.1M
26 Q1-6.15M
25 Q4-6.59M
25 Q3-6.86M
25 Q2-7.11M
25 Q1-7.33M
24 Q4-7.24M
24 Q3-6.8M
24 Q2-6.29M
24 Q1-6.14M
EBITDA (USD) · TTM
-8M-6M-4M-2M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
BFRG EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
26 Q2-5.99M
26 Q1-6.07M
25 Q4-6.49M
25 Q3-6.72M
25 Q2-6.93M
25 Q1-7.09M
24 Q4-6.97M
24 Q3-6.56M
24 Q2-6.04M
24 Q1-5.91M
Cash Flows (USD) · TTM
-6M-4M-2M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
BFRG Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
26 Q2-5.5M
26 Q1-5.42M
25 Q4-5.52M
25 Q3-5.61M
25 Q2-5.71M
25 Q1-5.51M
24 Q4-5.61M
24 Q3-5.36M
24 Q2-5.54M
24 Q1-5.54M
EPS (USD) · TTM
-1-0.75-0.5-0.25024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
BFRG EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
26 Q2-0.47
26 Q1-0.55
25 Q4-0.64
25 Q3-0.72
25 Q2-0.79
25 Q1-0.84
24 Q4-0.89
24 Q3-0.89
24 Q2-0.88
24 Q1-0.92
Expenses (USD) · TTM
-2M02M4M6M8MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
BFRG Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
26 Q26.22M
26 Q16.17M
25 Q46.62M
25 Q36.89M
25 Q27.12M
25 Q17.33M
24 Q47.24M
24 Q36.8M
24 Q26.35M
24 Q16.2M
Shares Outstanding · TTM
-1.5M-1M-500K024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
BFRG Shares Outstanding · TTM by quarter
PeriodShares Outstanding · TTM
26 Q2-768.93K
26 Q1-837K
25 Q4-1.01M
25 Q3-1.07M
25 Q2-894.04K
25 Q1-908.52K
24 Q4-943.65K
24 Q3-849.73K
24 Q2-769.62K
24 Q1-839.5K
Employee Count
02.557.5102022202320242025
BFRG Employee Count by quarter
PeriodEmployee Count
20259
20249
20234
20224
Free Cash Flow Yield
-125%-100%-75%-50%-25%0%med -45.35%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
BFRG Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-61.44%
Sep 26-58.11%
Aug 26-54.14%
Aug 26-50.17%
Aug 26-51.46%
Aug 26-70.92%
Jul 26-75.39%
Jul 26-71.41%
Jul 26-64.83%
Jul 26-60.64%
Jul 26-59.79%
Jun 26-63.89%
Jun 26-57.91%
Jun 26-67.71%
Jun 26-62.36%
May 26-55.23%
May 26-63.98%
May 26-70.77%
May 26-73.28%
May 26-69.25%
Apr 26-59.72%
Apr 26-48.64%
Apr 26-54.61%
Apr 26-40.3%
Mar 26-95.15%
Mar 26-86.21%
Mar 26-90.67%
Mar 26-90.92%
Feb 26-93.24%
Feb 26-100.82%
Feb 26-117.43%
Feb 26-94.66%
Jan 26-88.59%
Jan 26-74.81%
Jan 26-74.66%
Jan 26-67.11%
Jan 26-61.4%
Dec 25-56.77%
Dec 25-47.82%
Dec 25-49.13%
Dec 25-47.82%
Nov 25-54.04%
Nov 25-63.53%
Nov 25-54.05%
Nov 25-53.46%
Oct 25-45.94%
Oct 25-41.41%
Oct 25-40.01%
Oct 25-44.55%
Oct 25-40.84%
Sep 25-41.41%
Sep 25-44.55%
Sep 25-44.22%
Sep 25-51.59%
Aug 25-48.6%
Aug 25-46.31%
Aug 25-47.05%
Aug 25-44.75%
Aug 25-43.72%
Jul 25-37.39%
Jul 25-37.64%
Jul 25-37.64%
Jul 25-34.87%
Jun 25-37.64%
Jun 25-34.44%
Jun 25-33.63%
Jun 25-33.63%
May 25-33.23%
May 25-30.72%
May 25-32.47%
May 25-38.66%
May 25-37.59%
Apr 25-36.78%
Apr 25-40.99%
Apr 25-32.4%
Apr 25-52.34%
Mar 25-40.02%
Mar 25-38.66%
Mar 25-39.56%
Mar 25-36.62%
Feb 25-31.54%
Feb 25-23.13%
Feb 25-18.01%
Feb 25-23.05%
Jan 25-28.05%
Jan 25-27.47%
Jan 25-31.1%
Jan 25-31.1%
Jan 25-29.83%
Dec 24-29.83%
Dec 24-31.54%
Dec 24-29.7%
Dec 24-24.51%
Nov 24-30.66%
Nov 24-33.46%
Nov 24-28.91%
Nov 24-25.07%
Nov 24-29.8%
Oct 24-29.04%
Oct 24-27.85%
Price to Sales
0200400600med 266.85Mar 24Jun 24Oct 24Oct 25Feb 26May 26Sep 26
BFRG Price to Sales by quarter
PeriodPrice to Sales
Sep 2629.96
Sep 2631.67
Aug 2634
Aug 2636.68
Aug 2635.77
Aug 2665.48
Jul 2661.6
Jul 2665.04
Jul 2671.63
Jul 2676.58
Jul 2677.68
Jun 2672.68
Jun 2680.2
Jun 2668.59
Jun 2674.47
May 2684.08
May 2672.58
May 2665.63
May 2664.59
May 2668.35
Apr 2679.25
Apr 2697.31
Apr 2686.68
Apr 26117.44
Mar 2649.75
Mar 2654.9
Mar 2653.02
Mar 2652.88
Feb 2651.57
Feb 2647.69
Feb 2640.94
Feb 2650.79
Jan 2654.27
Jan 2664.27
Jan 2664.39
Jan 2671.64
Jan 2678.31
Dec 2584.7
Dec 25100.53
Dec 2597.86
Dec 25100.53
Nov 2588.97
Nov 2575.68
Nov 2588.95
Nov 25321.04
Oct 25373.58
Oct 25414.44
Oct 25429.03
Oct 25385.25
Oct 25420.28
Sep 25414.44
Sep 25385.25
Sep 25388.17
Sep 25332.72
Aug 25353.15
Aug 25370.66
Aug 25364.82
Nov 24286.24
Oct 24293.74
Oct 24306.24
Oct 24337.49
Oct 24336.24
Sep 24372.49
Sep 24301.24
Sep 24294.99
Sep 24301.24
Aug 24322.49
Aug 24319.99
Aug 24321.24
Aug 24322.49
Aug 24346.69
Jul 24341.01
Jul 24280.76
Jul 24300.09
Jul 24180.73
Jun 24196.65
Jun 24206.88
Jun 24284.17
Jun 24298.95
May 24328.5
May 24338.73
May 24323.96
May 24328.5
May 24292.54
Apr 24272.85
Apr 24253.16
Apr 24287.85
Apr 24308.48
Mar 24260.85
Mar 24286.85
Mar 24301.48
Mar 24315.3
Mar 24360.8
Feb 24316.92
Feb 24356.74
Feb 24407.12
Feb 24357.55
Jan 24572.08
Jan 24397.37
Jan 24208.03
Price to Book
02468med 4.44Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
BFRG Price to Book by quarter
PeriodPrice to Book
Sep 261.28
Sep 261.35
Aug 261.45
Aug 261.57
Aug 261.53
Aug 261.56
Jul 261.47
Jul 261.55
Jul 261.71
Jul 261.83
Jul 261.85
Jun 261.74
Jun 261.91
Jun 261.64
Jun 261.78
May 262.01
May 261.73
May 261.57
May 263.53
May 263.73
Apr 264.33
Apr 265.31
Apr 264.73
Apr 266.41
Mar 262.72
Mar 263
Mar 263.18
Mar 263.17
Feb 263.1
Feb 262.86
Feb 262.46
Feb 263.05
Jan 263.26
Jan 263.86
Jan 263.87
Jan 264.3
Jan 264.7
Dec 255.08
Dec 256.03
Dec 255.87
Dec 256.03
Nov 255.34
Nov 254.54
Nov 255.34
Nov 254.88
Oct 255.68
Oct 256.3
Oct 256.52
Oct 255.86
Oct 256.39
Sep 256.3
Sep 255.86
Sep 255.9
Sep 255.06
Aug 255.37
Aug 255.63
Aug 255.54
Aug 253.79
Aug 253.88
Jul 254.54
Jul 254.51
Jul 254.51
Jul 254.87
Jun 254.51
Jun 254.92
Jun 255.04
Jun 255.04
May 255.1
May 255.52
May 255.22
May 252.92
May 253.01
Apr 253.07
Apr 252.76
Apr 253.49
Apr 252.16
Mar 252.82
Mar 252.92
Mar 252.86
Mar 253.83
Feb 254.44
Feb 256.06
Feb 257.78
Feb 256.08
Jan 254.99
Jan 255.1
Jan 254.51
Jan 254.51
Jan 254.7
Dec 244.7
Dec 244.44
Dec 244.72
Dec 245.72
Nov 244.57
Nov 244.19
Nov 244.85
Nov 245.59
Nov 243.46
Oct 243.55
Oct 243.7
Bullfrog AI Holdings, Inc. Common Stock
BFRG
Stockpicker

Video analysis: BFRG

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: BFRG

BullFrog AI to Participate in September 2026 Investor Conferences

globenewswire.com · 8 Sep 2026

BullFrog AI to Participate in September 2026 Investor Conferences

GAITHERSBURG, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), an AI company using three complementary capabilities to turn complex biomedical data into actionable insights, announces its participation in the following upcoming investor conferences.

BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference

globenewswire.com · 22 Jul 2026

BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference

GAITHERSBURG, Md., July 22, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), an AI company using three complementary capabilities to turn complex biomedical data into actionable insights, announces that the Company's management team will participate in the BTIG Virtual Biotechnology Conference being held on July 28-29, 2026.

BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026

globenewswire.com · 21 Jul 2026

BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026

GAITHERSBURG, Md., July 21, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), an AI company using three complementary capabilities to turn complex biomedical data into actionable insights, announces that Vin Singh, Founder and Chief Executive Officer of BullFrog AI, will participate in the upcoming Water Tower Research Fireside Chat Series, taking place on Thursday, July 23, 2026 at 1:00 pm ET.

Water Tower Research Publishes Initiation of Coverage Report on BullFrog AI Holdings, Inc., "Helping Big Pharma Look Before It Leaps in Drug Discovery"

thenewswire.com · 24 Jun 2026

Water Tower Research Publishes Initiation of Coverage Report on BullFrog AI Holdings, Inc., "Helping Big Pharma Look Before It Leaps in Drug Discovery"

June 24, 2026, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on BullFrog AI Holdings, Inc. (NASDAQ: BFRG) titled, “Helping Big Pharma Look Before It Leaps in Drug Discovery”. The report can be accessed here. BullFrog AI Holdings, Inc. (NASDAQ: BFRG) is a Gaithersburg, Maryland-based AI company that is focused on the pharmaceutical R&D market. BullFrog uses AI to increase the success rate of drug development while reducing the time and investment it requires. The company commercializes a proprietary, end-to-end AI and ML platform that prepares biomedical data, identifies the biological drivers of disease, and supports development decisions. The platform targets a core inefficiency in drug development: bringing a new drug to market typically takes 10-15 years and $1-2 billion, and even then, roughly half of the drugs that reach Phase 3 still fail, often because developers picked the wrong target or could not identify which patients a drug actually helps.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.